公开(公告)号：EP3872181A1

公开(公告)日：2021-09-01

申请号：EP19877208.9

申请日：2019-10-24

申请人： School Corporation, Azabu Veterinary Medicine Educational Institution ,  Tella, Inc.

发明人： YAMASHITA, Tadashi ,  NAGANE, Masaki ,  IKEDA, Teruo ,  MIYATAKE, Shoichiro ,  OKAMOTO, Mariko

IPC分类号： C12N15/54 ,  A61K35/17 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C12N5/0783 ,  C12N5/10 ,  C12Q1/48 ,  G01N33/15 ,  G01N33/50 ,  C12N9/10

摘要： The prevent invention provides an activated T cell in which the expression of an immune checkpoint molecule is suppressed, a method for producing the T cell, and a method for screening for a substance that can be used in the production of the T cell. Specifically, the prevent invention includes, as solving means, a method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, the method comprising reducing or losing the function of UDP-glucose ceramide glucosyltransferase (UGCG) or ganglioside in a T cell, and a T cell produced or induced by the aforementioned method.

公开(公告)号：EP3868407A1

公开(公告)日：2021-08-25

申请号：EP19873926.0

申请日：2019-10-11

申请人： Osaka University

发明人： FURUKAWA, Takahisa ,  CHAYA, Taro

IPC分类号： A61K45/00 ,  A61K31/436 ,  A61K38/13 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P27/02 ,  C12Q1/48 ,  G01N33/15 ,  G01N33/50

摘要： The present invention provides a medicament for improving or preventing a symptom relating to a retina and/or light reception, the medicament comprising, as an active ingredient, a substance capable of maintaining or enhancing the phosphorylation state of Unc119; a method for screening for a substance capable of improving or preventing a symptom relating to a retina and/or light reception, the method comprising the step of selecting a substance capable of inhibiting calcineurin, or selecting a substance capable of activating casein kinase 2; and an agent for inhibiting retinal degeneration and an agent for protecting a retina, the agents each comprising, as an active ingredient, a substance capable of maintaining or enhancing the phosphorylation state of Unc119.

公开(公告)号：EP3853582A1

公开(公告)日：2021-07-28

申请号：EP19766248.9

申请日：2019-09-10

申请人： Klaria Pharma Holding AB

发明人： GRILC, Blaz ,  PLANINSEK, Odon ,  BOYER, Scott ,  HUBINETTE, Fredrik ,  MASCHER, Erik

IPC分类号： G01N13/00 ,  G01N33/15

公开(公告)号：EP3848394A1

公开(公告)日：2021-07-14

申请号：EP20217144.3

申请日：2011-04-08

申请人： Critical Care Diagnostics, Inc.

发明人： SNIDER, James V.

IPC分类号： C07K16/28 ,  C07K16/18 ,  C07K16/46 ,  G01N33/53 ,  C12N5/12 ,  G01N33/15

摘要： Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.

公开(公告)号：EP3831409A1

公开(公告)日：2021-06-09

申请号：EP19844718.7

申请日：2019-07-31

申请人： ONO Pharmaceutical Co., Ltd.

发明人： TSUMORI, Yuki ,  NAKANISHI, Yasutomo ,  FUJIMURA, Shinsei

IPC分类号： A61K45/00 ,  A61K31/711 ,  A61K45/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C12N9/99 ,  C12N15/113 ,  C12Q1/48 ,  C12Q1/6809 ,  G01N33/15 ,  G01N33/50

摘要： The present disclosure addresses the problem of providing a novel therapeutic agent, for cartilage disease, that has cartilage-regenerating action. Because substances having SIK2 inhibitory action have chondrocyte-differentiation-inducing action, a therapeutic agent formed so as to contain a substance having SIK2-inhibitory action is useful as a therapeutic agent, having cartilage-regenerating action, for cartilage damage or cartilage diseases such as osteoarthritis.

公开(公告)号：EP3778889A1

公开(公告)日：2021-02-17

申请号：EP20189559.6

申请日：2012-09-28

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： IGAWA, Tomoyuki ,  ISHII, Shinya ,  FUNAKI, Miho ,  HIRONIWA, Naoka ,  SHIMIZU, Shun

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61P37/02 ,  C07K16/00 ,  C40B40/10 ,  G01N33/15 ,  G01N33/50

摘要： Disclosed is a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, wherein an antigen-binding domain in each of the antigen-binding molecules comprises at least one amino acid residue that changes the antigen-binding activity of the antigen-binding molecule depending on ion concentration conditions. Also disclosed are a composition comprising a plurality of polynucleotide molecules each encoding the antigen-binding molecules, a composition comprising a plurality of vectors each comprising the polynucleotide molecules, a method for selecting the antigen-binding molecules, a method for isolating the polynucleotide molecules, a method for producing the antigen-binding molecules, and a pharmaceutical composition comprising any of the antigen-binding molecules.

公开(公告)号：EP3763375A1

公开(公告)日：2021-01-13

申请号：EP19763545.1

申请日：2019-03-05

申请人： Foundation for Biomedical Research and Innovation at Kobe

发明人： TAGUCHI, Akihiko

IPC分类号： A61K35/28 ,  A61K35/15 ,  A61P1/00 ,  A61P1/18 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P13/12 ,  A61P25/00 ,  A61P25/28 ,  G01N33/15 ,  G01N33/48

摘要： The present invention provides a cell preparation in which a proportion of leukocyte in a normal form and an undesired component containing at least one selected from the group consisting of erythrocyte, deformed cell, platelet and aggregate (undesired component count/leukocyte count) is not more than a predetermined value. The aforementioned predetermined value is preferably 37.0%. In addition, the cell preparation of the present invention can be utilized for the treatment of ischemic diseases such as cerebral infarction, myocardial infarction, limb ischemia, renal infarction, pulmonary infarction, splenic infarction, the intestinal infarction, Buerger disease, cerebrovascular dementia, diabetic nephropathy microangiopathy, diabetic cardiac failure and the like.

公开(公告)号：EP3740757A1

公开(公告)日：2020-11-25

申请号：EP19741302.4

申请日：2019-01-18

申请人： Eutropics Pharmaceuticals, Inc.

发明人： CARDONE, Michael

IPC分类号： G01N33/574 ,  G01N33/15 ,  G01N33/50

公开(公告)号：EP3011281B1

公开(公告)日：2020-11-04

申请号：EP14726955.9

申请日：2014-05-26

申请人： Syntegon Technology GmbH

发明人： MAGA, Iulian ,  VOGT, Martin ,  SCHLIPF, Jens

IPC分类号： G01G9/00 ,  B65B3/28 ,  G01N23/12 ,  G01N33/15 ,  G01G17/00 ,  A61J3/07

公开(公告)号：EP3730606A1

公开(公告)日：2020-10-28

申请号：EP18892944.2

申请日：2018-12-18

申请人： Kyoto University

发明人： TOGUCHIDA, Junya ,  KAWAI, Shunsuke ,  YOSHITOMI, Hiroyuki ,  CANTAS, Alev

IPC分类号： C12N5/077 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  C12N5/10

摘要： The present invention provides a method for inducing osteogenic differentiation, the method comprising the following steps of: (1) culturing pluripotent stem cells under feeder-free conditions, (2) culturing the cells in a mixed culture medium of an osteogenic induction medium and a pluripotent stem cell medium, the mixed culture medium containing a ROCK inhibitor and a retinoic acid receptor α or β agonist, and (3) culturing the cells in an osteogenic induction medium containing the retinoic acid receptor α or β agonist. The method for inducing osteogenic differentiation according to the present invention is a simple, short-term, highly efficient and highly reproducible one-procedure method for inducing osteogenic differentiation, wherein the method is suitable for bone regeneration therapies, the development of bone metabolic drugs and the development of novel therapies for bone diseases.